

AKR1C1 RABBIT PAB

货号: S220045

产品全名: AKR1C1 兔多抗

基因符号: C9; DDI; DDH; DDH1; H-37; HBAB; MBAB; HAKRC; DDI/DD2; 2-ALPHA-HSD; 20-ALPHA-HSD

UNIPROT ID: Q04828 (Gene Accession - NP_001344)

背景: This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the reaction of progesterone to the inactive form 20-alpha-hydroxy-progesterone. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. [provided by RefSeq, Jul 2008]

抗原: Synthetic peptide of human AKR1C1

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-100; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism, Signal Transduction, Developmental Biology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human prostate cancer tissue using 220045(AKR1C1 Antibody) at a dilution of 1/50(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with the synthetic peptide and then with 220045(Anti-AKR1C1 Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using 220045(Anti-AKR1C1 Antibody) at a dilution of 1/50.



In comparison with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with synthetic peptide and then with D260850(Anti-AKR1C1 Antibody) at dilution 1/50.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
